Nitec, PAZ GmbH deal

Nitec received exclusive, worldwide rights to PAZ's tarenflurbil to treat chronic inflammation and pain. Nitec plans to start a Phase II trial of the inhibitor of NF-kappa B (NF-kB) and activator pr...